Maat Pharma S.a. Stock
€7.04
Your prediction
Maat Pharma S.a. Stock
Pros and Cons of Maat Pharma S.a. in the next few years
Pros
Cons
News
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to